Vaccination against tumor neovascularization: Promise and reality

被引：26

作者：

Rafii, S ^{[1
]}

机构：

[1] Cornell Univ, Coll Med, Div Hematol Oncol, New York, NY 10021 USA

来源：

CANCER CELL | 2002年 / 2卷 / 06期

关键词：

D O I：

10.1016/S1535-6108(02)00208-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immunization against angiogenic-associated antigens selectively expressed on tumor vasculature provides for a novel strategy to block tumor growth.The feasibility of this approach has recently been borne out in several reports demonstrating that the protein or DNA of angiogenic molecules, such as VEGF-R2, can be used as vaccines to generate an effective cytotoxic T cell and antibody response against tumor vessels, thereby blocking tumor growth and metastasis.

引用

页码：429 / 431

页数：3

共 10 条

[1] Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen [J].

Cheng, WF ;

Hung, CF ;

Chai, CY ;

Hsu, KF ;

He, LM ;

Ling, M ;

Wu, TC .

JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (05) :669-678

[2] HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story [J].

Hicklin, DJ ;

Marincola, FM ;

Ferrone, S .

MOLECULAR MEDICINE TODAY, 1999, 5 (04) :178-186

[3] Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis [J].

Li, YW ;

Wang, MN ;

Li, HL ;

King, KD ;

Bassi, R ;

Sun, HJ ;

Santiago, A ;

Hooper, AT ;

Bohlen, P ;

Hicklin, DJ .

JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (12) :1575-1584

[4] Immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken homologous integrin β3 [J].

Lou, YY ;

Wei, YQ ;

Yang, L ;

Zhao, X ;

Tian, L ;

Lu, Y ;

Wen, YJ ;

Liu, F ;

Huang, MJ ;

Kang, B ;

Xiao, F ;

Su, JM ;

He, QM ;

Xie, XJ ;

Mao, YQ ;

Lei, S ;

Liu, JY ;

Lou, F ;

Zhou, LQ ;

Peng, F ;

Jiang, Y ;

Hu, B .

IMMUNOLOGICAL INVESTIGATIONS, 2002, 31 (01) :51-69

[5] Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: Time to take stock! [J].

Marx, GM ;

Steer, CB ;

Harper, P ;

Pavlakis, N ;

Rixe, O ;

Khayat, D .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1446-1448

[6]

NIETHAMMER AG, 2002, NAT MED 1104

[7] Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development [J].

Plum, SM ;

Holaday, JW ;

Ruiz, A ;

Madsen, JW ;

Fogler, WE ;

Fortier, AH .

VACCINE, 2000, 19 (9-10) :1294-1303

[8]

St Croix B, 2000, SCIENCE, V289, P1197

[9] Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen [J].

Wei, YQ ;

Huang, MJ ;

Yang, L ;

Zhao, X ;

Tian, L ;

Lu, Y ;

Shu, JM ;

Lu, CJ ;

Niu, T ;

Kang, B ;

Mao, YQ ;

Liu, F ;

Wen, YJ ;

Lei, S ;

Luo, F ;

Zhou, LQ ;

Peng, F ;

Jiang, Y ;

Liu, JY ;

Zhou, H ;

Wang, QR ;

He, QM ;

Xiao, F ;

Lou, YY ;

Xie, XJ ;

Li, Q ;

Wu, Y ;

Ding, ZY ;

Hu, B ;

Hu, M ;

Zhang, W .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (20) :11545-11550

[10] Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine [J].

Wei, YQ ;

Wang, QR ;

Zhao, X ;

Yang, L ;

Tian, L ;

Lu, Y ;

Kang, B ;

Lu, CJ ;

Huang, MJ ;

Lou, YY ;

Xiao, F ;

He, QM ;

Shu, JM ;

Xie, XJ ;

Mao, YQ ;

Lei, S ;

Luo, F ;

Zhou, LQ ;

Liu, CE ;

Zhou, H ;

Jiang, Y ;

Peng, F ;

Yuan, LP ;

Li, Q ;

Wu, Y ;

Liu, JY .

NATURE MEDICINE, 2000, 6 (10) :1160-1166

← 1 →